Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 6, 2003, Pages 554-565

  Nishizato, Yohei ^b   Ieiri, Ichiro ^a   Suzuki, Hiroshi ^b   Kimura, Miyuki ^b   Kawabata, Kiyoshi ^b   Hirota, Takeshi ^b   Takane, Hiroshi ^b   Irie, Shin ^b   Kusuhara, Hiroyuki ^b   Urasaki, Yoko ^b   Urae, Akinori ^b   Higuchi, Shun ^b   Otsubo, Kenji ^b   Sugiyama, Yuichi ^b  

^a TOTTORI UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; DNA; DRUG METABOLITE; ORGANIC ANION TRANSPORTER; PRAVASTATIN; RMS 416; VALINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DEGRADATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; OUTCOMES RESEARCH; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; STATISTICAL SIGNIFICANCE; ASIAN; BIOSYNTHESIS; BIOTRANSFORMATION; CAUCASIAN; GENE FREQUENCY; GENETICS; HAPLOTYPE; JAPAN; NEGRO; NOMENCLATURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOTRANSFORMATION; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HAPLOTYPES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; ORGANIC ANION TRANSPORT POLYPEPTIDE C; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; POLYMORPHISM, GENETIC; PRAVASTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TERMINOLOGY;

EID: 0038209381     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00060-2     Document Type: Article

References (37)

1. Evans WE, Relling M. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.
2. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for individual differences in drug response. Annu Rev Genomics Hum Genet 2001;2:9-39.
3. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269-96.
4. Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab 2002;3:289-309.
5. Yamazaki M, Suzuki H, Sugiyama Y. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 1996;13:497-513.
6. Hatanaka T, Honda S, Sasaki S, Katayama K, Koizumi T. Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin. J Pharmacokinet Biopharm 1998;26:329-47.
7. Triscari J, O'Donnell D, Zinny M, Pan HY. Gastrointestinal absorption of pravastatin in healthy subjects. J Clin Pharmacol 1995;35:142-4.
8. Tamai I, Takanaga H, Maeda H, Ogihara T, Yoneda M, Tsuji A. Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm Res 1995;12:1727-32.
9. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 1993;264:G36-44.
10. Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, Sugiyama Y. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res 1999;16:904-8.
11. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999;274:37161-8.
12. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000;278:G156-64.
13. Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2000; 276:9626-30.
14. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999;274:17159-63.
15. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C. Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001; 276:35669-75.
16. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, et al. Genetic polymorphisms of human organic anion transporter OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2001;302: 804-13.
17. Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, et al. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 2002; 277:43058-63.
18. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. Biotransformation of pravastatin sodium in human. Drug Metab Dispos 1991;19:740-8.
19. Arai M, Serizawa N, Terahara A. Pravastatin sodium (CS-415): a novel cholesterol-lowering agent which inhibits HMG-CoA reductase. Annu Rep Sankyo Res Lab 1988;40:1-38.
20. Singhvi SM, Pan HY, Morrison RA, Willard DA. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990;29:239-43.
21. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, et al. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 1999;274:13675-80.
22. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 2001;59:1277-86.
23. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, et al. Functional involvement of rat organic anion transporter 3 (rOAT3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther 2002;300:746-53.
24. Xie HG, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41:815-50.
25. Cepeda MS, Farrar JT, Roa JH, Boston R, Meng QC, Ruiz F, et al. Ethnicity influences morphine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2001;70:351-61.
26. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, et al. Frequency of C3435T polymorphism of the MDR1 gene in African people. Lancet 2001;358:383-4.
27. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular identification and characterization of novel member of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000; 273:251-60.
28. Nebert DW. Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics 2000;10: 279-90.
29. Ziegler K, Hummelsiep S. Hepatoselective carrier-mediated sodium-independent uptake of pravastatin and pravastatin-lactone. Biochim Biophys Acta 1993;1153:23-33.
30. Yamazaki M, Tokui T, Ishigami M, Sugiyama Y. Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. Biopharm Drug Dispos 1996;17:775-89.
31. Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res 1996;13:1559-64.
32. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43.
33. Suzuki A, Tirona RG, Leake B, Echizen H, Takahashi H, Miyake F, et al. Polymorphisms in the digoxin uptake transporter OATP-8, among Japanese, African-, and European-American subjects [abstract]. Clin Pharmacol Ther 2002;71:P104.
34. Ito S, Ieiri I, Tanabe M, Sizuki A, Higuchi S, Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001;11:175-84.
35. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002;12:395-405.
36. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 2001;18:1262-9.
37. Tsuji A. Tissue selective drug delivery utilizing carrier-mediated transport systems. J Control Release 1999;62: 239-44.